Northern Trust Corp Acquires 51,960 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Northern Trust Corp lifted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 10.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 547,050 shares of the company's stock after purchasing an additional 51,960 shares during the period. Northern Trust Corp owned 0.54% of Day One Biopharmaceuticals worth $6,931,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Virtus ETF Advisers LLC raised its stake in shares of Day One Biopharmaceuticals by 7.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company's stock worth $346,000 after purchasing an additional 1,805 shares in the last quarter. Nebula Research & Development LLC raised its stake in shares of Day One Biopharmaceuticals by 95.9% during the 4th quarter. Nebula Research & Development LLC now owns 19,804 shares of the company's stock worth $251,000 after purchasing an additional 9,697 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $219,000. Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $481,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock worth $135,000 after acquiring an additional 9,603 shares during the last quarter. Institutional investors own 87.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DAWN. Wedbush reissued an "outperform" rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th. HC Wainwright reissued a "buy" rating and set a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. JPMorgan Chase & Co. decreased their target price on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Finally, Needham & Company LLC decreased their target price on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $30.57.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 13,964 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $87,414.64. Following the sale, the chief executive officer now directly owns 145,737 shares of the company's stock, valued at approximately $912,313.62. This represents a 8.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Charles N. York II sold 4,282 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the sale, the chief financial officer now directly owns 265,231 shares in the company, valued at approximately $1,660,346.06. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,725 shares of company stock valued at $167,299 in the last ninety days. 6.20% of the stock is currently owned by corporate insiders.

Day One Biopharmaceuticals Stock Performance

NASDAQ DAWN remained flat at $6.27 on Friday. The company's stock had a trading volume of 1,050,670 shares, compared to its average volume of 1,116,135. The stock's fifty day moving average is $7.23 and its two-hundred day moving average is $10.46. Day One Biopharmaceuticals, Inc. has a 52-week low of $6.08 and a 52-week high of $16.76. The stock has a market capitalization of $635.54 million, a P/E ratio of -6.09 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analyst estimates of $30.28 million. Analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.